evaluating checkpoint blockade rechallenge after til therapy in refractory melanoma
Published 1 month ago • 60 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
1:11
exploring til therapy & io rechallenge in checkpoint refractory melanoma
-
2:48
combining checkpoint blockade therapies in melanoma
-
14:32
evaluating the use of immune checkpoint inhibitors in melanoma
-
9:56
how does braf rechallenge and retreatment impact tumor histology beyond melanoma?
-
0:34
managing acute and long-term side effects in checkpoint inhibitors for melanoma
-
1:06
evaluating the suitability of checkpoint inhibitors with biomarkers in patients with melanoma
-
2:08
assessing textbook outcomes in borderline resectable stage iiib-d and iv melanoma
-
33:17
evaluating biomarkers for response to neoadjuvant immune checkpoint blockade..
-
3:58
16 years cancer-free thanks to immunotherapy: sharon belvin's melanoma story
-
8:17
immune checkpoint inhibitors
-
5:10
introduction to immune checkpoint inhibitor (ici) immunotherapy
-
1:30
treatment response assessment in melanoma and the challenge of pseudoprogression with immunotherapy
-
0:53
the others study: optimal duration of checkpoint inhibitors in solid tumors
-
1:09
progress in treatment approaches for patients with melanoma
-
0:51
what role will tils play in treating patients with melanoma?
-
4:58
expert report on neoadjuvant immune checkpoint inhibitors for melanoma
-
7:06
checkpoint inhibitor rechallenge after immune-related adverse events in gu cancers
-
1:45
mechanisms of resistance to checkpoint inhibitors in melanoma
-
4:36
dr. van akkooi on crossover or rechallenge with pembrolizumab in patients with resected melanoma
-
6:43
til cell therapy in melanoma
-
31:24
updates on immune checkpoint blockade resistant melanoma
-
0:47
bo-112: enhancing immune-checkpoint inhibition in solid tumors